12/4
07:18 am
dbvt
DBV Technologies (NASDAQ:DBVT) was upgraded by analysts at Guggenheim to a "strong-buy" rating. They now have a $35.00 price target on the stock.
Low
Report
DBV Technologies (NASDAQ:DBVT) was upgraded by analysts at Guggenheim to a "strong-buy" rating. They now have a $35.00 price target on the stock.
12/3
07:02 am
dbvt
DBV Technologies (NASDAQ:DBVT) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
Low
Report
DBV Technologies (NASDAQ:DBVT) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
12/2
04:00 pm
dbvt
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025
Low
Report
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025
12/2
03:41 pm
dbvt
DBV Technologies (NASDAQ:DBVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
DBV Technologies (NASDAQ:DBVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
02:05 pm
dbvt
DBV Technologies (NASDAQ:DBVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
DBV Technologies (NASDAQ:DBVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/12
12:01 am
dbvt
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years [Yahoo! Finance]
Medium
Report
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years [Yahoo! Finance]
11/11
11:50 pm
dbvt
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
Medium
Report
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
11/10
01:20 pm
dbvt
Food Allergy Market Valued at USD 3 Billion across the 7MM, Projected to Grow at CAGR of 11.3% by 2034 | DelveInsight [Yahoo! Finance]
Low
Report
Food Allergy Market Valued at USD 3 Billion across the 7MM, Projected to Grow at CAGR of 11.3% by 2034 | DelveInsight [Yahoo! Finance]
11/4
04:30 pm
dbvt
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Medium
Report
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
11/3
04:30 pm
dbvt
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
Low
Report
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
11/3
04:25 pm
dbvt
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025
Low
Report
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025
10/30
06:43 pm
dbvt
DBV Technologies (ENXTPA:DBV) Faces Ongoing Losses as Revenue Forecasts Outpace French Biotech Market [Yahoo! Finance]
Low
Report
DBV Technologies (ENXTPA:DBV) Faces Ongoing Losses as Revenue Forecasts Outpace French Biotech Market [Yahoo! Finance]
10/30
04:46 pm
dbvt
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors [Yahoo! Finance]
Medium
Report
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors [Yahoo! Finance]
10/30
04:30 pm
dbvt
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
Medium
Report
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
10/30
03:00 am
dbvt
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
Medium
Report
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
10/29
06:47 pm
dbvt
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
Medium
Report
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
10/29
01:05 pm
dbvt
DBV Technologies (NASDAQ:DBVT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
DBV Technologies (NASDAQ:DBVT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
10/28
04:25 pm
dbvt
DBV Technologies Reports Third Quarter 2025 Financial Results
Low
Report
DBV Technologies Reports Third Quarter 2025 Financial Results
10/6
05:30 pm
dbvt
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq [Yahoo! Finance]
Low
Report
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq [Yahoo! Finance]
10/6
05:02 pm
dbvt
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
Low
Report
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
9/29
01:25 pm
dbvt
Peanut Allergy Clinical Trial Pipeline: Insights into a Growing Landscape with 12+ Companies Advancing Novel Treatments| DelveInsight [Yahoo! Finance]
Low
Report
Peanut Allergy Clinical Trial Pipeline: Insights into a Growing Landscape with 12+ Companies Advancing Novel Treatments| DelveInsight [Yahoo! Finance]
9/18
04:49 pm
dbvt
DBV Technologies Announces Resignation of Board Member [Yahoo! Finance]
Low
Report
DBV Technologies Announces Resignation of Board Member [Yahoo! Finance]
9/18
04:30 pm
dbvt
DBV Technologies Announces Resignation of Board Member
Low
Report
DBV Technologies Announces Resignation of Board Member
9/5
04:30 pm
dbvt
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
Low
Report
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq